ACCEPTABILITY AND WRITING FREQUENCY OF ADVANCED DIRECTIVES IN ONCO-DERMATOLOGY PATIENTS

Melanoma Clinical Trial

— PADAONCODERM  

Official title:

ACCEPTABILITY AND WRITING FREQUENCY OF ADVANCED DIRECTIVES IN ONCO-DERMATOLOGY PATIENTS

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03822988
• Other study ID #: PSS-2018/PADAONCODERM
• Status: Recruiting
• Start date: January 21, 2019
• Est. completion date: June 20, 2019

Study information

• Verified date: January 2019
• Source: Central Hospital, Nancy, France
• Contact: Anne-Claire BURSZTEJN
• Phone: 0383157146
• Email: ac-bursztejn[@]chru-nancy.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The law about advance directives is evolving but, in France, few people write it.

Te main endpoint of this research is to estimate the proportion of patients who have written their advance directives or considering doing so in onco-dermatologic population. If this rate remains low, some insights on the reasons will be able to be advanced looking at the point of view and opinion of patients about this topic.

Seconds endpoints are :

For patients against or not planning to write it, understand their reasons

Estimate the proportion of patients requesting information and understand how they would like to receive it.

Investigate a possible association between the stage of the oncological disease and the positioning of the patient concerning advance directives.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 150
• Est. completion date: June 20, 2019
• Est. primary completion date: June 20, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

> 18 ya

With one of the diagnoses below:

• Melanoma

• Skin lymphoma

• Meckel Carcinoma

• localy advanced or metastatic Basal cell carcinoma or squamous cell carcinoma

Exclusion Criteria:

Patients not in possession of all of its cognitive abilities Patients who can't read patients who don't speak french

Related Conditions & MeSH terms

• Advance Directives
• Carcinoma
• Carcinoma, Basal Cell
• Carcinoma, Squamous Cell
• Melanoma
• Metastatic Basal Cell Carcinoma
• Oncology
• Skin Cancer
• Skin Lymphoma
• Skin Neoplasms
• Skin Squamous Cell Carcinoma

Intervention

Other:
• no intervention, only complete a survey
we will ask patients to answer to a survey

Locations

Country	Name	City	State
France	CHRU Nancy-Brabois hospital	Vandœuvre-lès-Nancy

Sponsors (1)

Lead Sponsor	Collaborator
Central Hospital, Nancy, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Writing by the patient of its advance directives	Writing by the patient of his advance directves and, if not writing, positioning of the patient (rather favorable or rather unfavorable) as to the writing of his advance directives.	when the patient complete the survey
Secondary	reason for not writing advance directives	In patients who have not written their advance directives: reason for not writing the advance directives.	when the patient complete the survey
Secondary	Patient wishing to be more informed about the adavance directives during its management and, if so, by what means.		when the patient complete the survey